NORD Stock Overview
Norda ASA, a biotechnology company, engages in the cancer diagnostic activities.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr41.00|
|52 Week High||kr0|
|52 Week Low||kr0|
|1 Month Change||0%|
|3 Month Change||0%|
|1 Year Change||n/a|
|3 Year Change||127.78%|
|5 Year Change||382.35%|
|Change since IPO||-99.59%|
Recent News & Updates
|NORD||NO Biotechs||NO Market|
Return vs Industry: Insufficient data to determine how NORD performed against the Norwegian Biotechs industry.
Return vs Market: Insufficient data to determine how NORD performed against the Norwegian Market.
|NORD Average Weekly Movement||n/a|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||7.4%|
|10% most volatile stocks in NO Market||12.4%|
|10% least volatile stocks in NO Market||4.2%|
Stable Share Price: Insufficient data to determine NORD's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine NORD's volatility change over the past year.
About the Company
Norda ASA, a biotechnology company, engages in the cancer diagnostic activities. The company is involved in the research and development of Genefec, a diagnostic screening test for colorectal cancer. It also invests and trades in securities, real estates, and other assets.
Norda Fundamentals Summary
|NORD fundamental statistics|
Is NORD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NORD income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
|Earnings per share (EPS)||84.01|
|Net Profit Margin||91.17%|
How did NORD perform over the long term?See historical performance and comparison
14.6%Current Dividend Yield
Is Norda undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NORD (NOK41) is trading below our estimate of fair value (NOK162.05)
Significantly Below Fair Value: NORD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NORD is good value based on its PE Ratio (0.5x) compared to the European Biotechs industry average (40x).
PE vs Market: NORD is good value based on its PE Ratio (0.5x) compared to the Norwegian market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NORD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NORD is good value based on its PB Ratio (1.4x) compared to the NO Biotechs industry average (3.9x).
How is Norda forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Norda has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Norda performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: NORD has a high level of non-cash earnings.
Growing Profit Margin: NORD's current net profit margins (91.2%) are higher than last year (48.2%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NORD's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare NORD's past year earnings growth to its 5-year average.
Earnings vs Industry: NORD earnings growth over the past year (943.3%) exceeded the Biotechs industry -5.2%.
Return on Equity
High ROE: Whilst NORD's Return on Equity (288.82%) is outstanding, this metric is skewed due to their high level of debt.
How is Norda's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: NORD's short term assets (NOK563.6M) exceed its short term liabilities (NOK481.4M).
Long Term Liabilities: NORD has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NORD has more cash than its total debt.
Reducing Debt: NORD's debt to equity ratio has increased from 77.9% to 303.5% over the past 5 years.
Debt Coverage: NORD's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: NORD's interest payments on its debt are well covered by EBIT (72.9x coverage).
What is Norda current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: NORD's dividend (14.63%) is higher than the bottom 25% of dividend payers in the Norwegian market (2.9%).
High Dividend: NORD's dividend (14.63%) is in the top 25% of dividend payers in the Norwegian market (6.64%)
Stability and Growth of Payments
Stable Dividend: Too early to tell whether NORD's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if NORD's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (7.1%), NORD's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Insufficient data to calculate cash payout ratio to determine if its dividend payments are covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Frode Westvold, Ph D., serves as Chief Executive Officer and General Manager of Norda ASA. Dr. Westvold serves as Chief Executive Officer and Partner of Andenaesgrupen/AS Tanja.He served as Director o...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Norda ASA's employee growth, exchange listings and data sources
- Name: Norda ASA
- Ticker: NORD
- Exchange: OTCNO
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr208.701m
- Shares outstanding: 5.09m
- Website: https://www.nordasa.no
Number of Employees
- Norda ASA
- Stortingsgaten 28
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.